Adamas Pharmaceuticals (ADMS) Reports Q4 Loss, Tops Revenue Estimates

By Nasdaq6 days ago

Adamas Pharmaceuticals (ADMS) came out with a quarterly loss of $0.64 per share versus the Zacks Consensus Estimate of a loss of $0.53. This compares to loss of $0.83 per share a year ago. These figures are adjusted for non-recurring items.

Continue read on nasdaq.com